Search

Your search keyword '"Hayllar, Jeremy"' showing total 40 results
Start Over Author "Hayllar, Jeremy"
40 results on '"Hayllar, Jeremy"'

1. A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial

Author

McKetin, Rebecca, Degan, Tayla J., Saunders, Lucy, Nguyen, Long, Dore, Gregory, Shoptaw, Steven, Farrell, Michael, Degenhardt, Louisa, Kelly, Peter J., Turner, Alyna, Clare, Philip J., Dean, Olivia M., Arunogiri, Shalini, Colledge-Frisby, Samantha, Koeijers, Juanita, Goodman-Meza, David, Sinclair, Barbara, Reid, David, Hill, Harry, Hayllar, Jeremy, Christmass, Michael, Cordaro, Frank, Lundin, Robert, Liaw, Willy, Liu, Danica, Holyoak, Ellie, Wu, Brian Tid-Fung, Keygan, Joel, Kontogiannis, Ava, Palmer, Lily, Morrison, Caity, Wrobel, Anna, Hyland, Bec, Byrne, Marianne, Russell, Samantha, Zahra, Emma, and Berk, Michael

Published
2024
Full Text
View/download PDF

4. Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs

Author

Broady, Timothy R., Valerio, Heather, Alavi, Maryam, Wheeler, Alice, Silk, David, Martinello, Marianne, Conway, Anna, Milat, Andrew, Dunlop, Adrian, Murray, Carolyn, Henderson, Charles, Amin, Janaki, Read, Phillip, Marks, Philippa, Degenhardt, Louisa, Stevens, Annabelle, Prain, Bianca, Hayllar, Jeremy, Reid, David, Montebello, Mark, Wade, Alexandra, Christmass, Michael, Cock, Victoria, Dore, Gregory J., Treloar, Carla, and Grebely, Jason

Published
2024
Full Text
View/download PDF

7. Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study

Author

Grebely, Jason, Dore, Gregory J., Silk, David, Bath, Nicky, Treloar, Carla, Milat, Andrew, Dunlop, Adrian, Amin, Janaki, Holden, Jo, Murray, Carolyn, Henderson, Charles, Leadbeatter, Kyle, Day, Emma, Habraken, Nikitah, Dawson, Olivia, Degenhardt, Louisa, Scott, Clarke, Read, Phillip, Valerio, Heather, Tillakeratne, Shane, Marks, Philippa, Jayasinghe, Indika, Martinez, Maria, Reid, Hannah, Gleeson, Valerie, Van Dyk, Jodi, Mercade, Gerard Estivill, Marshall, Alison D., Obeid, Stephanie, Wheeler, A., Hooshyar, Samira Hosseini, Catlett, Beth, Verich, Andrey, Conway, Anna, Erratt, Amanda, Wheeler, Alice, Ezard, Nadine, Reid, David, Gorton, Carla, Hayllar, Jeremy, Lam, Thao, Datta, Prasun, Wade, Alex, Spruce, Sally, Cock, Vicky, Cornwell, Mark, Zohrab, Krista, Christmass, Michael, Connelly, Craig, Cooper, Angela, Montebello, Mark, Cherry, Robert, Dyer, Julie, Arawal, Shikha, Press, Elke, Horasak, Nadine, Lewis, Rhondda, Carthew, Astrid, Morris, Daniel, Donohue, Kathy, Griffiths, Kathy, Lana, Jason Dalla, Shin, Sue, Graf, Connie, Hampson, Adele, Qian, Siyu, Brown, Danielle, Lautier, Amber, Curran, Cate, Burns, Carina, Raidu, Ravina, Stolzenhein, Kylie, Brabender, Wanda, Somes, Kelly, Abram, Nargis, Turne, Rick, Larter, Stuart, Goodberg, Fiona, Luksza, Jennifer, Hall, Michelle, Hazelwood, Susan, Ismay, Charlotte, McClurg, Belinda, Mincham, Cherie, Barlow, Kali, Hoskins, Anita, Salisbury, Kate, Markham, Julie, Talmet, Jacky, Dunn, Sandy, Mitchell, Amanda, McKinnon, Andrew, Smyth, Fionnualh, Snell, Lisa, Laing, Elizabeth, Clark, Martin, Dorigo, Justin, Carman, Louise, Fergusson, Brent, Puszka, Bonny, Duncan, Gai, Baker, Fiona, Walsh, Jayde, Walsh, Leeann, Adey, Sara, Hinton, Rodd, Joyce, Melanie, Woods, Cheryl, Jenart, Alain, Everingham, Hope, Jansen, Louisa, Pepolim, Lucy, Clark, Kathy, Murphy, Lyn, Iliffe, Joel, Cheng, Qinglu, Cunningham, Evan B., and Shih, Sophy T.F.

Published
2024
Full Text
View/download PDF

10. Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study

Author

Wheeler, Alice, Valerio, Heather, Cunningham, Evan B., Martinello, Marianne, Barocas, Joshua A., Colledge-Frisby, Samantha, Treloar, Carla, Amin, Janaki, Henderson, Charles, Read, Phillip, Matthews, Gail V., Dunlop, Adrian J., Gorton, Carla, Hayllar, Jeremy, Alavi, Maryam, Murray, Carolyn, Marks, Phillipa, Silk, David, Degenhardt, Louisa, Dore, Gregory J., and Grebely, Jason

Published
2022
Full Text
View/download PDF

11. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study

Author

Valerio, Heather, Alavi, Maryam, Conway, Anna, Silk, David, Treloar, Carla, Martinello, Marianne, Milat, Andrew, Dunlop, Adrian, Murray, Carolyn, Henderson, Charles, Amin, Janaki, Read, Phillip, Marks, Philippa, Degenhardt, Louisa, Stevens, Annabelle, Prain, Bianca, Hayllar, Jeremy, Reid, David, Montebello, Mark, Wade, Alexandra, Christmass, Michael, Cock, Victoria, Dore, Gregory J, and Grebely, Jason

Published
2022
Full Text
View/download PDF

12. Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay

Author

LiveRLife Study Group, Lamoury, Francois M. J., Bajis, Sahar, Hajarizadeh, Behzad, Marshall, Alison D., Martinello, Marianne, Ivanova, Elena, Catlett, Beth, Mowat, Yasmin, Marks, Philippa, Amin, Janaki, Smith, Julie, Ezard, Nadine, Cock, Victoria, Hayllar, Jeremy, Persing, David H., Kleman, Marika, Cunningham, Philip, Dore, Gregory J., Applegate, Tanya L., and Grebely, Jason

Published
2018

13. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia

Author

Bajis, Sahar, Maher, Lisa, Treloar, Carla, Hajarizadeh, Behzad, Lamoury, Francois M.J., Mowat, Yasmin, Schulz, Marcel, Marshall, Alison D., Cunningham, Evan B., Cock, Victoria, Ezard, Nadine, Gorton, Carla, Hayllar, Jeremy, Smith, Julie, Whelan, Michelle, Martinello, Marianne, Applegate, Tanya L., Dore, Gregory J., and Grebely, Jason

Published
2018
Full Text
View/download PDF

17. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study

Author

Conway, Anna, primary, Valerio, Heather, additional, Alavi, Maryam, additional, Silk, David, additional, Treloar, Carla, additional, Hajarizadeh, Behzad, additional, Marshall, Alison D., additional, Martinello, Marianne, additional, Milat, Andrew, additional, Dunlop, Adrian, additional, Murray, Carolyn, additional, Prain, Bianca, additional, Henderson, Charles, additional, Amin, Janaki, additional, Read, Phillip, additional, Marks, Pip, additional, Degenhardt, Louisa, additional, Hayllar, Jeremy, additional, Reid, David, additional, Gorton, Carla, additional, Lam, Thao, additional, Christmass, Michael, additional, Wade, Alexandra, additional, Montebello, Mark, additional, Dore, Gregory J., additional, and Grebely, Jason, additional

Published
2022
Full Text
View/download PDF

23. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study

Author

Valerio, Heather, primary, Alavi, Maryam, additional, Silk, David, additional, Treloar, Carla, additional, Martinello, Marianne, additional, Milat, Andrew, additional, Dunlop, Adrian, additional, Holden, Jo, additional, Henderson, Charles, additional, Amin, Janaki, additional, Read, Phillip, additional, Marks, Philippa, additional, Degenhardt, Louisa, additional, Hayllar, Jeremy, additional, Reid, David, additional, Gorton, Carla, additional, Lam, Thao, additional, Dore, Gregory J, additional, and Grebely, Jason, additional

Published
2020
Full Text
View/download PDF

26. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.

Author

Valerio, Heather, Alavi, Maryam, Silk, David, Treloar, Carla, Martinello, Marianne, Milat, Andrew, Dunlop, Adrian, Holden, Jo, Henderson, Charles, Amin, Janaki, Read, Phillip, Marks, Philippa, Degenhardt, Louisa, Hayllar, Jeremy, Reid, David, Gorton, Carla, Lam, Thao, Dore, Gregory J, and Grebely, Jason

Subjects
RNA analysis, THERAPEUTIC use of narcotics, HEPATITIS C prevention, SCIENTIFIC observation, CORRECTIONAL institutions, CONFIDENCE intervals, POINT-of-care testing, VIRAL load, ANALGESICS, ANTIVIRAL agents, QUESTIONNAIRES, DISEASE prevalence, DESCRIPTIVE statistics, HOMELESSNESS, ODDS ratio, DRUG abusers
Abstract

Background Evaluating progress towards hepatitis C virus (HCV) elimination is critical. This study estimated prevalence of current HCV infection and HCV treatment uptake among people who inject drugs (PWID) in Australia. Methods The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage is an observational study of PWID attending drug treatment clinics and needle and syringe programs (NSPs). Participants completed a questionnaire including self-reported treatment history and underwent point-of-care HCV RNA testing (Xpert HCV Viral Load Fingerstick; Cepheid). Results Between May 2018 and September 2019, 1443 participants were enrolled (64% injected drugs in the last month, 74% receiving opioid agonist therapy [OAT]). HCV infection status was uninfected (28%), spontaneous clearance (16%), treatment-induced clearance (32%), and current infection (24%). Current HCV was more likely among people who were homeless (adjusted odds ratio, 1.47; 95% confidence interval, 1.00–2.16), incarcerated in the previous year (2.04; 1.38–3.02), and those injecting drugs daily or more (2.26; 1.43–2.42). Among those with previous chronic or current HCV, 66% (n = 520/788) reported HCV treatment. In adjusted analysis, HCV treatment was lower among females (.68;.48–.95), participants who were homeless (.59;.38–.96), and those injecting daily or more (.51;.31–.89). People aged ≥45 years (1.46; 1.06–2.01) and people receiving OAT (2.62; 1.52–4.51) were more likely to report HCV treatment. Conclusions Unrestricted direct-acting antiviral therapy access in Australia has yielded high treatment uptake among PWID attending drug treatment and NSPs, with a marked decline in HCV prevalence. To achieve elimination, PWID with greater marginalization may require additional support and tailored strategies to enhance treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐ and post‐universal access to direct‐acting antiviral treatment in Australia: The LiveRLife study.

Author

Bajis, Sahar, Grebely, Jason, Hajarizadeh, Behzad, Applegate, Tanya, Marshall, Alison D., Ellen Harrod, Mary, Byrne, Jude, Bath, Nicky, Read, Phillip, Edwards, Michael, Gorton, Carla, Hayllar, Jeremy, Cock, Victoria, Peterson, Steven, Thomson, Claire, Weltman, Martin, Jefferies, Meryem, Wood, William, Haber, Paul, and Ezard, Nadine

Subjects
HEPATITIS C virus, THERAPEUTICS, NURSING assessment, LIVER diseases, HEPATITIS C, HIV testing kits, GENERAL practitioners, NURSE practitioners
Abstract

Gaps in hepatitis C virus (HCV) testing, diagnosis, liver disease assessment and treatment uptake among people who inject drugs (PWID) persist. We aimed to describe the cascade of HCV care among PWID in Australia, prior to and following unrestricted access to direct‐acting antiviral (DAA) treatment. Participants enrolled in an observational cohort study between 2014 and 2018 provided fingerstick whole‐blood samples for dried blood spot, Xpert HCV Viral Load and venepuncture samples. Participants underwent transient elastography and clinical assessment by a nurse or general practitioner. Among 839 participants (mean age 43 years), 66% were male (n = 550), 64% (n = 537) injected drugs in the previous month, and 67% (n = 560) reported currently receiving opioid substitution therapy. Overall, 45% (n = 380) had detectable HCV RNA, of whom 23% (n = 86) received HCV treatment within 12 months of enrolment. HCV treatment uptake increased from 2% in the pre‐DAA era to 38% in the DAA era. Significant liver fibrosis (F2‐F4) was more common in participants with HCV infection (38%) than those without (19%). Age 50 years or older (aOR, 2.88; 95% CI, 1.18‐7.04) and attending a clinical follow‐up with nurse (aOR, 3.19; 95% CI, 1.61‐6.32) or physician (aOR, 11.83; 95% CI, 4.89‐28.59) were associated with HCV treatment uptake. Recent injection drug use and unstable housing were not associated with HCV treatment uptake. HCV treatment uptake among PWID has increased markedly in the DAA era. Evaluation of innovative and simplified models of care is required to further enhance treatment uptake. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. Speeding: a review of self-reported effects of amphetamine-type stimulants (ATS).

Author

Green, Bob, Hayllar, Jeremy, and Anderson, Carrick

Subjects
*SUBSTANCE abuse & psychology, *AMPHETAMINES, *ILLUSION (Philosophy), *ECSTASY (Drug), *MOLECULAR structure, *PARANOIA, *SELF-evaluation, *SOCIAL participation, *SUBSTANCE abuse, *SYSTEMATIC reviews, *POSITIVE psychology, *DISEASE prevalence
Abstract

Speeding: A review of self-reported effects of Amphetamine-type Stimulants (ATS). Background: Despite well-publicized adverse effects, Amphetamine-type Stimulants (ATS) continue to be widely used. The self-report of ATS users provides a valuable source of information regarding the diverse range of ATS effects. Examining the self-reported acute effects of ATS users supports a fuller understanding of potential drivers, inhibitors, perceived benefits and negative consequences of ATS use. Method: A systematic review of studies reporting the prevalence of self-reported effects was undertaken. Effects meeting the review criteria were categorised using a computerised dictionary of terms, and their point prevalence estimated. Results: Over half of the MDMA and amphetamine participants reported increased sociability, energy, talkativeness and positive mood. There was a range of psychological and physiological effects commonly reported by MDMA users, not reported by amphetamine users. Almost a third of MDMA users reported hallucinations and 20% paranoia, however, physical violence was not frequently examined or reported. No studies meeting the review criteria were located that described the frequency of self-reported methamphetamine effects. Unlike areas such as alcohol and cannabis where there is an established literature examining drug expectancies, there is limited research into amphetamine or methamphetamine expectancies which impedes a comprehensive understanding of particular effects which reinforce use, especially for recreational users. Conclusions: A wide range of self-reported ATS effects and their prevalence were estimated. The absence of studies documenting self-reported methamphetamine effects and studies on ATS expectancies are notable gaps in the literature. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

33. An overview of take-home naloxone programs in Australia

Author

Dwyer, Robyn, primary, Olsen, Anna, additional, Fowlie, Carrie, additional, Gough, Chris, additional, van Beek, Ingrid, additional, Jauncey, Marianne, additional, Lintzeris, Nicholas, additional, Oh, Grace, additional, Dicka, Jane, additional, Fry, Craig L., additional, Hayllar, Jeremy, additional, and Lenton, Simon, additional

Published
2018
Full Text
View/download PDF

34. Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay.

Author

Lamoury, Francois M. J., Bajis, Sahar, Hajarizadeh, Behzad, Marshall, Alison D., Martinello, Marianne, Ivanova, Elena, Catlett, Beth, Mowat, Yasmin, Marks, Philippa, Amin, Janaki, Smith, Julie, Ezard, Nadine, Cock, Victoria, Hayllar, Jeremy, Persing, David H., Kleman, Marika, Cunningham, Philip, Dore, Gregory J., Applegate, Tanya L., and Grebel, Jason

Subjects
HEPATITIS C virus, HEPATITIS C, ANTIVIRAL agents, VENOUS puncture, MEDICAL care
Abstract

Point-of-care hepatitis C virus (HCV) RNA testing is advantageous, enabling diagnosis of active infection in a single visit. This study evaluated the sensitivity and specificity of the Xpert HCV Viral Load Finger-Stick assay (Xpert HCV VL FS) for HCV RNA detection (finger-stick) and the Xpert HCV Viral Load assay (plasma) compared with the Abbott RealTime HCV Viral Load assay by venepuncture. Plasma and finger-stick capillary whole-blood samples were collected from participants in an observational cohort in Australia. Of 223 participants enrolled, HCV RNA was detected in 40% of participants (85 of 210) with available Xpert HCV Viral Load testing. Participants receiving HCV therapy were excluded from subsequent analyses (n = 16). Sensitivity of the Xpert HCV Viral Load assay for HCV RNA quantification in plasma collected by venepuncture was 100.0% (95% confidence interval [CI] 96.9%-100.0%) and specificity was 100.0% (95% CI, 94.4%-100.0%). Sensitivity of the Xpert HCV VL FS assay for HCV RNA quantification in samples collected by finger-stick was 100.0% (95% CI, 93.9%-100.0%) and specificity was 100.0% (95% CI, 96.6%-100.0%). The Xpert HCV VL FS test can accurately detect active infection from a finger-stick sample in 1 hour allowing single-visit HCV diagnosis. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results